C. R. Bard, Inc., together with its subsidiaries, engages in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company sells a range of products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities worldwide. Products The company offers its products in four major product group categories, including vascular, urology, oncology and surgical specialties. The company also has a product group of other products. Vascular Products The company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. These products include percutaneous transluminal angioplasty (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters. The company offers Ultraverse and VascuTrak PTA catheters and Crosser CTO catheter in the small-vessel segment of the PVD market. The company’s line of peripheral vascular stents, covered stents and vascular grafts includes the Flair AV (arterial venous) Access Stent Graft, E•Luminexx and LifeStar Iliac Stents, and the LifeStent family of stents approved for use in the superficial femoral and proximal popliteal arteries. Its vena cava filters product line includes devices that can be either permanently implanted or retrieved after the threat of blood clots traveling from the lower extremities to a patient’s lungs has passed. The company also offers products for the treatment of ESRD through a line of long-term dialysis catheters, including GlidePath, Equistream, Decathlon, Hickman and Reliance catheters. The company also offers a portfolio of automatic core needle biopsy devices, including MaxCore, Magnum, the Mission semi-automatic biopsy device and the Marquee disposable core biopsy instrument. The company’s Vacora and Finesse devices combine the benefits of a vacuum-assisted biopsy technology with a portable, self-contained needle system for the diagnosis of breast tumors. The company offers various products across the percutaneous breast biopsy and tissue marker segments. The EnCor and EnCor Enspire breast biopsy systems allow for ultrasound-, stereotactic- and MRI-guided breast biopsy procedures; and its breast tissue markers include the SenoMark, StarchMark and Gel Mark product lines. Urology Products The company’s urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. The company offers Foley catheters, including the infection control Foley catheter (Bardex I.C. Foley catheter), which reduces the rate of urinary tract infections. In 2013, the company acquired Rochester Medical Corporation and its line of intermittent self-catheters and male external catheters, primarily used in non-acute settings. In January 2016, the company acquired Liberator Medical, Inc., a durable medical equipment supplier to vertically integrate and expand its presence in the non-acute segment of the market. Other products include fecal incontinence products; brachytherapy devices and radioactive seeds used to treat prostate cancer; intermittent urinary drainage catheters, urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; and surgical slings and pelvic floor repair products for women’s health. The company markets the proprietary line of StatLock catheter stabilization devices, which are used primarily to secure peripheral intravenous catheters, thereby reducing restarts and other complications. These devices are also used to secure various other types of catheters sold by the company and other companies, including Foley catheters. In addition, the company markets the Arctic Sun system with proprietary ArcticGel pads providing therapy for patie
cr bard inc (BCR:New York)
730 Central Avenue
Murray Hill, NJ 07974
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for BCR.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.